Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice

Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacol Res Perspect
Hauptverfasser: Tao, Linfen, Guo, Xiaolong, Xu, Min, Wang, Yumeng, Xie, Wenhua, Chen, Hong, Ma, Mengyao, Li, Xi
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7753983/
https://ncbi.nlm.nih.gov/pubmed/33474802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.700
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge